Public Health

The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...

Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.

The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.

Crinecerfont, a first-in-class therapy, improved androgen control and reduced reliance on high-dose glucocorticoids for patients with congenital adrenal hyperplasia.

The FDA has approved tirzepatide, the first-ever drug option to treat moderate to severe obstructive sleep apnea in adults with obesity.

Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.

The nasal spray is the first vaccine for the prevention of influenza that does not need to be administered by a health care provider.

The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.

The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.